Although no definite evidence exists and the tumor microenvironment, such as infiltration of CD8-positive T cells in the specimen, has not been evaluated, it is possible that activation of the immune profile of the tumor microenvironment with induction of immunogenic cell death may be involved. These findings suggest that the high expression of PD-L1 in tumors for preoperative treatment and the increased immunogenicity of tumors by radiation therapy for the treatment of recurrent lesions may have contributed to the efficacy of ICI, respectively. The gene discussed is CD8A; the disease is neoplasm.